Properties (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:chemicalFormula |
thiazole derivatives
thiazole ring C20H25N3O2S amine compounds phenyl group dimethylamino_group |
| gptkbp:clinicalTrials |
Phase II
anxiety disorders Phase III Phase I major depressive disorder |
| gptkbp:collaborations |
gptkb:ABC_University
DEF_Research_Institute |
| gptkbp:compatibleWith |
moderate
|
| gptkbp:complications |
fatigue
dry mouth weight gain |
| gptkbp:composedOf |
multi-step synthesis
reduction reaction coupling reaction |
| gptkbp:conference |
Annual Neuroscience Meeting
International_Conference_on_Psychiatry |
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| gptkbp:endOfLife |
6 hours
|
| gptkbp:evaluates |
promising
|
| gptkbp:funding |
private investment
government grant |
| https://www.w3.org/2000/01/rdf-schema#label |
WPC-991
|
| gptkbp:impact |
dizziness
nausea insomnia |
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
not marketed
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operational_status |
ongoing
|
| gptkbp:origin |
N-(4-(4-(dimethylamino)phenyl)-1,3-thiazol-2-yl)-2-(4-methylphenyl)propanamide
|
| gptkbp:patentAssignee |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:patentStatus |
patented
|
| gptkbp:produces |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:publications |
Journal of Medicinal Chemistry
Clinical_Psychopharmacology_Journal Neuropsychopharmacology_Journal |
| gptkbp:releaseYear |
2010
|
| gptkbp:research |
under investigation
|
| gptkbp:research_focus |
mental health
neuropharmacology |
| gptkbp:safety_features |
acceptable
|
| gptkbp:targets |
serotonin receptor
norepinephrine receptor |
| gptkbp:triggerType |
reuptake inhibitor
|
| gptkbp:uses |
antidepressant
|
| gptkbp:waterManagement |
urine
|
| gptkbp:weight |
373.55 g/mol
|